by Madaline Spencer | Aug 27, 2026
Tracey Dawson, PhD, Senior Vice President, US Therapeutic Area Head Neuroscience at Novartis, discusses the collaboration between Novartis, SMAshing My Limits, and Becoming rentABLE, striving to make travel accessible. Spinal muscular atrophy (SMA) is a...
by Madaline Spencer and Scott Harwood | Aug 26, 2026
The US Food and Drug Administration (FDA) has approved Imaavy (nipocalimab) for the treatment of patients ages 12 years and older with warm autoimmune hemolytic anemia (wAIHA) who are currently or previously treated with corticosteroids. wAIHA is a rare hematologic...
by Madaline Spencer | Aug 24, 2026
Gaia Coppock, MD, Nephrologist and Associate Professor of Clinical Medicine at the University of Pennsylvania, discusses patient experiences with IgA nephropathy (IgAN). IgAN is characterized by the accumulation of IgA antibodies in the kidneys. In the...
by Madaline Spencer | Aug 21, 2026
The US Food and Drug Administration (FDA) has granted accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), also known as DTX401, in patients eight years and older with glycogen storage disease type 1a (GSD1a). GSD1a is a rare metabolic disorder that...
by Madaline Spencer | Aug 21, 2026
Byron Wade, a patient with IgA nephropathy (IgAN), discusses his personal diagnostic journey and a recent study looking at other patients’ experiences. IgAN is characterized by the accumulation of IgA antibodies in the kidneys. In the early stages, patients...
